The research antibodies market is projected to grow at a rate of 5.9% in terms of value, from USD 3.35 Billion in 2019 to reach USD 5.33 Billion by 2030. The growing application of research antibodies in oncology is playing a major role in boosting the market growth. Cancer has a significant impact on society in the US and across the globe.
It has been estimated that 1,735,350 new cancer cases were diagnosed in the US, and 609,640 people suffered death from the disease. The number of new incidences of cancer is 439.2 per 100,000 men and women annually, and the number of cancer-related morbidities is 163.5 per 100,000 men and women annually. Moreover, it has been estimated that in 2019, 15,270 children and adolescents in the age range of 0-19 years were diagnosed with cancer, out of which 1,790 suffered death owing to the disease. In the year 2019, an estimated USD 147.30 billion was spent on cancer care in the US.
The market is witnessing an increasing demand, attributed to the growth of the biopharmaceutical industry. The biopharmaceutical industry is witnessing considerable growth in the past couple of years. The overall yearly revenue generation has risen from approximately USD 4.40 billion in the year 1990 to around USD 275.00 billion in the year 2018, experiencing growth of 6,250.0%, with industry contributing to more than 25.0% of the overall pharmaceutical market.
Request a Sample@ https://qyresearchmedical.com/sample/118940
Rising research activities in the field of stem cells is a significant factor driving the growth of the market. Cord blood stem cells find application in the treatment of more than 80 blood-related ailments, such as Sickle Cell Disease. It is projected that over 27 million babies across the globe are born with some kind of blood disorder. As per the World Health Organization, in 2008, 100,000 children were found to be suffering from thalassemia in India.
However, cost-prohibitive research antibodies and issues related to the quality of nontherapeutic antibodies may create hindrances in the growth of the market in the upcoming years.
Secondary antibodies assist in the detection, categorization, or purification of target antigens by binding it to the primary antibodies. As a significant proportion of primary antibodies are produced in a few host animal species, with approximately all of the antibodies belonging to the IgG class, it is economical for producers to supply prepared secondary antibodies that are appropriate for a majority of approaches and detection systems.
Antibody Type Outlook:
The monoclonal antibodies contributed to a larger market share in 2019. The application of monoclonal antibodies is in the treatment of diseases by targeting a specific antigen in the patient’s body. Applications for monoclonal antibodies comprise cancer, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, cardiovascular disease, transplant rejection, Crohn’s disease, psoriasis, and ulcerative colitis, among others. In these diseases, the monoclonal antibody interferes with the activities of a receptor, which is responsible for the development of the disease being treated.
Polyclonal antibodies are a combination of heterogeneous, which are commonly produced by different B cell clones in the body and are produced by injecting an immunogen into the body of an animal. These antibodies can identify and bind to several epitopes of a single antigen.
Immunohistochemistry held the second-largest market share in 2019. Immunohistochemistry is an advanced method of histopathology. Usually, immunohistochemistry is not used in the beginning but is further used when regular/routine histological testing is found to be insufficient for the purpose of diagnosis. This technology labels a protein by using primary antibodies and then deploys a secondary antibody to bind it with the primary one.
The benefits of immunohistochemistry comprise it can be used on fresh/frozen tissues, it is readily available, relatively economical, no involvement of live infectious agents, and least risk to human health, among others.
The pharmaceutical and biopharmaceutical industry contributed to the largest market share in 2019 and is likely to grow at a rate of 6.4% in the forecast period, owing to an extensive application of research antibodies in the process of drug development for recognizing and quantifying biomarkers, and in several other analytical procedures.
The research antibodies mar is witnessing an increasing demand, attributed to the growth of the pharmaceutical industry. The worldwide pharmaceutical market is estimated to surpass USD 1.50 trillion by the year 2023, increasing from USD 1.20 trillion in the years 2018, at an AGR of about 3.0%-6.0%. This increase is likely to be in parallel with the increase in the number of launched products that are estimated to be 54 in the year 2023.
The market in the North American region held the largest market share in 2019 and is estimated to witness a growth rate of 5.2% in the forecast period. The market dominance of the region is attributed to the growing prevalence of blood diseases and neurological disease, the presence of leading market players and increased investment in R&D activities, rising demand for personalized medicine, and technological advancements in proteomics research, among others.
The market in the European region held the second-largest market share in 2019 and is likely to grow at a rate of 5.7% in the forecast period.
- By product, primary antibodies held a larger market share in 2019 and are projected it witness the fastest growth rate of 6.2% in the forecast period.
- By product, primary antibodies held a larger market share in 2019. The benefits of western blots comprise the capacity to detect picogram levels of protein in a sample, enabling it to be used for several applications such as an effective early diagnostic tool.
- By application, oncology contributed to the largest market share in 2019 and is likely to grow at a rate of 5.7% in the period 2020-2030.
- By end-users, academics & research institutes held the second-largest market share in 2019 and are likely to grow at a rate of 5.2% in the forecast period.
- The market in the Asia Pacific region is projected to grow at the fastest rate of 7.1% in the forecast period.
Becton, Dickinson and Company, Lonza Group, Agilent Technologies, Abcam PLC, PerkinElmer, Inc., Bio-Rad Laboratories, Merck Millipore, F.Hoffmann-La Roche AG, Thermo Fisher Scientific, and Cell Signaling Technology Inc., among others.
The players operating in the market have undertaken a number of strategies related to the market in the period 2019-2020. Some of the key highlights are:
- In January 2019, Merck Millipore, a leading market player, made an announcement regarding the expansion of its end-to-end centers for bio development, comprising the inaugural of two new process development centers situated Boston (US) metropolitan and in the Shanghai (China) areas.
The industry offers numerous growth opportunities. Thus, a number of startups providing innovative products and technologies have been entering the market. Some of them include McroGenics, Innate Pharma, Immunocore, and AnaptysBio, among others.
Mergers and Acquisitions are an integral part of the research antibodies industry. Along with the companies operating in the market, other key market players have also been entering the industry.
- In January 2020, Abcam PLC, a leading market player, made an announcement about the acquisition of the Immunology and Proteomics business of Expedeon that comprises Innova and TGR Biosciences.
Reports and Data forecasts promising developments for increased adoption of research adoption. According to industry experts, the use of research antibodies in the biopharmaceutical industry, along with the research institutions, is garnering significant traction in the market. New companies entering the industry would emphasize designing and developing innovative products, thereby catering to the increasing requirement of end-use industries.
Segments covered in the report:
This report forecasts revenue growth at a global, regional & country level, and provides an analysis of the industry trends in each of the sub-segments from 2019 to 2030. The scope of the report can be defined as:
For the purpose of this study, Reports and Data have segmented the global research antibodies market on the basis of product, antibody type, technology, application, end-users, and region:
Product Outlook (Revenue, USD Million; 2019-2030)
- Primary Antibodies
- Secondary Antibodies
Antibody Type Outlook (Revenue, USD Million; 2019-2030)
Technology Outlook (Revenue, USD Million; 2019-2030)
- Western Blotting
- Flow Cytometry
- Enzyme-linked Immunosorbent Assay
Application Outlook (Revenue, USD Million; 2019-2030)
- Infectious Diseases
- Stem Cells
Industry Vertical Outlook (Revenue, USD Million; 2019-2030)
- Pharmaceutical & Biopharmaceutical
- Academic & Research Institutes
- Contract Research Organizations
Regional Outlook (Revenue, USD Million; 2019-2030)
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Saudi Arabia
- Rest of Middle East and Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/118940/1500
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: